常见SCI期刊的参考文献格式举例(上).doc

期刊名参考文献格式AAA Style GuideAbad, A., et al.1998Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. Am J Clin Oncol 21(2):151-4.Academy Mannagement RevAbad, A., Massuti, B., Blanco, E., Carrato, A., Maurel, J., Cervantes, A., Aranda, E., Anton, A., Vicent, J. M., Dorta, J., Garcia de Paredes, M. L., & Ariza, A. 1998. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. Am J Clin Oncol, 21(2): 151-154.Accounting ReviewAbad, A., B. Massuti, E. Blanco, A. Carrato, J. Maurel, A. Cervantes, E. Aranda, A. Anton, J. M. Vicent, J. Dorta, M. L. Garcia de Paredes, and A. Ariza. 1998. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. Am J Clin Oncol 21 (2):151-154.Accounts Chemical Res(1)Abad, A.; Massuti, B.; Blanco, E.; Carrato, A.; Maurel, J.; Cervantes, A.; Aranda, E.; Anton, A.; Vicent, J. M.; Dorta, J.; Garcia de Paredes, M. L.; Ariza, A.: Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology 1998, 21, 151-4.Acta Biomaterialia1 Abad A, Massuti B, Blanco E, Carrato A, Maurel J, Cervantes A, et al. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology 1998;21:151-4.Addiction1.ABAD, A., MASSUTI, B., BLANCO, E. et al. (1998) Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial, Am J Clin Oncol, 21, 151-4.Adv AgronomyAbad, A., Massuti, B., Blanco, E., Carrato, A., Maurel, J., Cervantes, A., Aranda, E., Anton, A., Vicent, J. M., Dorta, J., Garcia de Paredes, M. L., and Ariza, A. (1998). Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. Am J Clin Oncol 21, 151-4.Adv Drug Delivery Rev1 A. Abad, B. Massuti, E. Blanco, A. Carrato, J. Maurel, A. Cervantes, E. Aranda, A. Anton, J.M. Vicent, J. Dorta, M.L. Garcia de Paredes, A. Ariza, Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial, American journal of clinical oncology, 21 (1998) 151-154.Adv Nursing Science1.Abad A, Massuti B, Blanco E, et al. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology. Apr 1998;21(2):151-154.Adv Skin Wound Care1.Abad A, Massuti B, Blanco E, et al. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology. Apr 1998;21(2):151-154.Agri Forest MeteorologyAbad, A. et al., 1998. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. Am J Clin Oncol, 21(2): 151-4.AIDS1.Abad A, Massuti B, Blanco E, Carrato A, Maurel J, Cervantes A, et al. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. Am J Clin Oncol 1998,21:151-154.AIDS and Behavior1.Abad A, Massuti B, Blanco E, et al. Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology. Apr 1998;21(2):151-154.Ann Nuclear Part Sci1.Abad A, Massuti B, Blanco E, Carrato A, Maurel J, et al. 1998. American journal of clinical oncology 21:151-4Author-DateAbad, A., B. Massuti, et al. (1998). Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. Am J Clin Oncol 21(2): 151-154.BBA-Reviews on Cancer1 A. Abad, B. Massuti, E. Blanco, A. Carrato, J. Maurel, A. Cervantes, E. Aranda, A. Anton, J.M. Vicent, J. Dorta, M.L. Garcia de Paredes, A. Ariza, Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial, American journal of clinical oncology, 21 (1998) 151-154.Biochemical Biophysical Res1 A. Abad, B. Massuti, E. Blanco, A. Carrato, J. Maurel, A. Cervantes, E. Aranda, A. Anton, J.M. Vicent, J. Dorta, M.L. Garcia de Paredes, A. Ariza, Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial, Am J Clin Oncol 21 (1998) 151-154.Biochemistry1.Abad, A., Massuti, B., Blanco, E., Carrato, A., Maurel, J., Cervantes, A., Aranda, E., Anton, A., Vicent, J. M., Dorta, J., Garcia de Paredes, M. L., and Ariza, A. (1998) Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial, American journal of clinical oncology 21, 151-154.BMC Biotechnology1.Abad A, Massuti B, Blanco E, Carrato A, Maurel J, Cervantes A, Aranda E, Anton A, Vicent JM, Dorta J et al: Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology 1998, 21(2):151-154.BMC Cell Biology1.Abad A, Massuti B, Blanco E, Carrato A, Maurel J, Cervantes A, Aranda E, Anton A, Vicent JM, Dorta J et al: Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology 1998, 21(2):151-154.BMC Evolutionary Biology1.Abad A, Massuti B, Blanco E, Carrato A, Maurel J, Cervantes A, Aranda E, Anton A, Vicent JM, Dorta J et al: Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology 1998, 21(2):151-154.BMC Structural Biology1.Abad A, Massuti B, Blanco E, Carrato A, Maurel J, Cervantes A, Aranda E, Anton A, Vicent JM, Dorta J et al: Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology 1998, 21(2):151-154.Cancer CellAbad, A., Massuti, B., Blanco, E., Carrato, A., Maurel, J., Cervantes, A., Aranda, E., Anton, A., Vicent, J. M., Dorta, J., et al. (1998). Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology 21, 151-154.Cancer Cell International1.Abad A, Massuti B, Blanco E, Carrato A, Maurel J, Cervantes A, Aranda E, Anton A, Vicent JM, Dorta J et al: Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology 1998, 21(2):151-154.CellAbad, A., Massuti, B., Blanco, E., Carrato, A., Maurel, J., Cervantes, A., Aranda, E., Anton, A., Vicent, J.M., Dorta, J., et al. (1998). Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical oncology 21, 151-154.Cell and Chromosome1.Abad A, Massuti B, Blanco E, Carrato A, Maurel J, Cervantes A, Aranda E, Anton A, Vicent JM, Dorta J et al: Seventy-two hour epirubicin infusion plus quinidine in unresectable and metastatic adenocarcinoma of the pancreas: a phase II trial. American journal of clinical onco